Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oportuzumab monatox - Carisma Therapeutics

Drug Profile

Oportuzumab monatox - Carisma Therapeutics

Alternative Names: 4D5MOCB-ETA; Anti-ECAM exotoxin A fusion protein; oportuzumab monatox-qqrs; Proxinium; VB-4847; VB-845; VB4-845; Vicineum; Vysyneum

Latest Information Update: 29 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Zurich
  • Developer Carisma Therapeutics; National Cancer Institute (USA); Qilu Pharmaceutical; Viventia Biotechnologies
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bladder cancer; Head and neck cancer
  • Discontinued Liver cancer; Ovarian cancer

Most Recent Events

  • 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
  • 02 Mar 2023 Suspended - Phase-II for Bladder cancer in Canada (Intravesicular)
  • 02 Mar 2023 Suspended - Phase-III for Bladder cancer (Late-stage disease, Second-line therapy or greater) in Canada (Intravesicular)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top